Clinical Trials Arena on MSN
AbbVie’s skin disease drug posts Phase III win as market competition heats up
This late-stage readout comes as companies explore the potential of novel mechanisms of action in HS.
3don MSN
AbbVie’s skin disease drug hits phase 3 goal, but efficacy falls short of benchmarks: analyst
AbbVie Inc. ABBV on Thursday shared topline results from its Phase 3 INTREPID study evaluating lutikizumab in adults and adolescents with moderate to severe hidradenitis suppurativa (HS). The ...
This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results